A unifying gene signature for adenoid cystic cancer identifies parallel MYB-dependent and MYB-independent therapeutic targets

Oncotarget

Volumn 5, Issue 24, 2014, Pages 12528-12542

  Gao, Ruli ^a   Cao, Chunxia ^a   Zhang, Min ^a   Lopez, Maria Cecilia ^a   Yan, Yuanqing ^a   Chen, Zirong ^a   Mitani, Yoshitsugu ^b   Zhang, Li ^b   Zajac Kaye, Maria ^a   Liu, Bin ^b   Wu, Lizi ^a   Renne, Rolf ^a   Baker, Henry V ^a   El Naggar, Adel ^b   Kaye, Frederic J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adenoid cystic cancer; Extracellular matrix; MYB salivary gland cancer

Indexed keywords

MESSENGER RNA; MICRORNA; NOTCH1 RECEPTOR; TRANSCRIPTION FACTOR RUNX1; NFIB PROTEIN, HUMAN; NOTCH1 PROTEIN, HUMAN; NUCLEAR FACTOR I; ONCOPROTEIN; RUNX1 PROTEIN, HUMAN;

ADENOID CYSTIC CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CELL STRUCTURE; CELLS BY BODY ANATOMY; COMPLEX FORMATION; CONTROLLED STUDY; DEPLETION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; EXTRACELLULAR MATRIX GENE; GENE ACTIVATION; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NFIB GENE; NONHUMAN; NOTCH1 GENE; ONCOGENE; ONCOGENE MYB; RUNX1 GENE; SALIVARY GLAND CELL; SOMATIC MUTATION; VCAN GENE; ANIMAL; BIOSYNTHESIS; GENETICS; METABOLISM; NONOBESE DIABETIC MOUSE; SCID MOUSE; XENOGRAFT;

ANIMALS; CARCINOMA, ADENOID CYSTIC; CORE BINDING FACTOR ALPHA 2 SUBUNIT; GENE REARRANGEMENT; GENES, MYB; HETEROGRAFTS; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MICRORNAS; NFI TRANSCRIPTION FACTORS; ONCOGENE PROTEINS V-MYB; ONCOGENE PROTEINS, FUSION; RECEPTOR, NOTCH1; RNA, MESSENGER;

EID: 84921396345     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2985     Document Type: Article

References (79)

1. L Barnes JE, P Reichart, D Sidransky (2005). World Health Organization International Classification of Tumors. Pathology and Genetics of Head and Neck Tumors. Lyon: IARC Press).
2. Tonon G, Modi S, Wu L, Kubo A, Coxon AB, Komiya T, O'Neil K, Stover K, El-Naggar A, Griffin JD, Kirsch IR and Kaye FJ. t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet. 2003; 33(2):208-213.
3. Tirado Y, Williams MD, Hanna EY, Kaye FJ, Batsakis JG and El-Naggar AK. CRTC1/MAML2 fusion transcript in high grade mucoepidermoid carcinomas of salivary and thyroid glands and Warthin's tumors: implications for histogenesis and biologic behavior. Genes Chromosomes Cancer. 2007; 46(7):708-715.
4. Komiya T, Coxon A, Park Y, Chen WD, Zajac-Kaye M, Meltzer P, Karpova T and Kaye FJ. Enhanced activity of the CREB co-activator Crtc1 in LKB1 null lung cancer. Oncogene. 29(11):1672-1680.
5. Coxon A, Rozenblum E, Park YS, Joshi N, Tsurutani J, Dennis PA, Kirsch IR and Kaye FJ. Mect1-Maml2 fusion oncogene linked to the aberrant activation of cyclic AMP/CREB regulated genes. Cancer Res. 2005; 65(16):7137-7144.
6. Cao C, Gao R, Zhang M, Amelio AL, Fallahi M, Chen Z, Gu Y, Hu C, Welsh EA, Engel BE, Haura EB, Cress WD, Wu L, Zajac-Kaye M and Kaye FJ. Role of LKB1-CRTC1 on Glycosylated COX-2 and response to COX-2 Inhibition in lung cancer. J Natl Cancer Inst. 2015; 107(1):11.
7. Choi S, Sano D, Cheung M, Zhao M, Jasser SA, Ryan AJ, Mao L, Chen WT, El-Naggar AK and Myers JN. Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(16):5081-5089.
8. Phuchareon J, Ohta Y, Woo JM, Eisele DW and Tetsu O. Genetic profiling reveals cross-contamination and misidentification of 6 adenoid cystic carcinoma cell lines: ACC2, ACC3, ACCM, ACCNS, ACCS and CAC2. PloS one. 2009; 4(6):e6040.
9. El-Naggar AK, Kaye FJ and Stenman G. The 3rd Salivary Gland Tumor Workshop meeting report. Head & neck. 2013; 35(8):1057-1060.
10. Moskaluk CA, Baras AS, Mancuso SA, Fan H, Davidson RJ, Dirks DC, Golden WL and Frierson HF, Jr. Development and characterization of xenograft model systems for adenoid cystic carcinoma. Laboratory investigation; a journal of technical methods and pathology. 2011; 91(10):1480-1490.
11. Persson M, Andren Y, Mark J, Horlings HM, Persson F and Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(44):18740-18744.
12. Golay J, Basilico L, Loffarelli L, Songia S, Broccoli V and Introna M. Regulation of hematopoietic cell proliferation and differentiation by the myb oncogene family of transcription factors. International journal of clinical & laboratory research. 1996; 26(1):24-32.
13. Oh IH and Reddy EP. The myb gene family in cell growth, differentiation and apoptosis. Oncogene. 1999; 18(19):3017-3033.
14. Lieu YK and Reddy EP. Conditional c-myb knockout in adult hematopoietic stem cells leads to loss of self-renewal due to impaired proliferation and accelerated differentiation. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(51):21689-21694.
15. Klempnauer K-H. (2004). Target Genes Of V-Myb And C-Myb. Myb Transcription Factors: Their Role in Growth, Differentiation and Disease.
16. Thompson MA, Rosenthal MA, Ellis SL, Friend AJ, Zorbas MI, Whitehead RH and Ramsay RG. c-Myb down-regulation is associated with human colon cell differentiation, apoptosis, and decreased Bcl-2 expression. Cancer Res. 1998; 58(22):5168-5175.
17. Malaterre J, Carpinelli M, Ernst M, Alexander W, Cooke M, Sutton S, Dworkin S, Heath JK, Frampton J, McArthur G, Clevers H, Hilton D, Mantamadiotis T and Ramsay RG. c-Myb is required for progenitor cell homeostasis in colonic crypts. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(10):3829-3834.
18. Drabsch Y, Robert RG and Gonda TJ. MYB suppresses differentiation and apoptosis of human breast cancer cells. Breast cancer research: BCR. 2010; 12(4):R55.
19. O'Neil J, Tchinda J, Gutierrez A, Moreau L, Maser RS, Wong KK, Li W, McKenna K, Liu XS, Feng B, Neuberg D, Silverman L, DeAngelo DJ, Kutok JL, Rothstein R, DePinho RA, et al. Alu elements mediate MYB gene tandem duplication in human T-ALL. The Journal of experimental medicine. 2007; 204(13):3059-3066.
20. Gonda TJ and Metcalf D. Expression of myb, myc and fos proto-oncogenes during the differentiation of a murine myeloid leukaemia. Nature. 1984; 310(5974):249-251.
21. Shen-Ong GL. The myb oncogene. Biochimica et biophysica acta. 1990; 1032(1):39-52.
22. Lipsick JS and Wang DM. Transformation by v-Myb. Oncogene. 1999; 18(19):3047-3055.
23. Ramsay RG, Barton AL and Gonda TJ. Targeting c-Myb expression in human disease. Expert opinion on therapeutic targets. 2003; 7(2):235-248.
24. Ramsay RG and Gonda TJ. MYB function in normal and cancer cells. Nature reviews. 2008; 8(7):523-534.
25. Geurts JM, Schoenmakers EF, Roijer E, Astrom AK, Stenman G and van de Ven WJ. Identification of NFIB as recurrent translocation partner gene of HMGIC in pleomorphic adenomas. Oncogene. 1998; 16(7):865-872.
26. Nilsson M, Panagopoulos I, Mertens F and Mandahl N. Fusion of the HMGA2 and NFIB genes in lipoma. Virchows Arch. 2005; 447(5):855-858.
27. Grunder A, Qian F, Ebel TT, Mincheva A, Lichter P, Kruse U and Sippel AE. Genomic organization, splice products and mouse chromosomal localization of genes for transcription factor Nuclear Factor One. Gene. 2003; 304:171-181.
28. Mayr C, Hemann MT and Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science. 2007; 315(5818):1576-1579.
29. Wang X, Hulshizer RL, Erickson-Johnson MR, Flynn HC, Jenkins RB, Lloyd RV and Oliveira AM. Identification of novel HMGA2 fusion sequences in lipoma: evidence that deletion of let-7 miRNA consensus binding site 1 in the HMGA2 3' UTR is not critical for HMGA2 transcriptional upregulation. Genes Chromosomes Cancer. 2009; 48(8):673-678.
30. Ross JS, Wang K, Rand JV, Sheehan CE, Jennings TA, Al-Rohil RN, Otto GA, Curran JC, Palmer G, Downing SR, Yelensky R, Lipson D, Balasubramanian S, Garcia L, Mahoney K, Ali SM, et al. Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies. The American journal of surgical pathology. 2014; 38(2):235-238.
31. Stephens PJ, Davies HR, Mitani Y, Van Loo P, Shlien A, Tarpey PS, Papaemmanuil E, Cheverton A, Bignell GR, Butler AP, Gamble J, Gamble S, Hardy C, Hinton J, Jia M, Jayakumar A, et al. Whole exome sequencing of adenoid cystic carcinoma. The Journal of clinical investigation. 2013; 123(7):2965-2968.
32. Ho AS, Kannan K, Roy DM, Morris LG, Ganly I, Katabi N, Ramaswami D, Walsh LA, Eng S, Huse JT, Zhang J, Dolgalev I, Huberman K, Heguy A, Viale A, Drobnjak M, et al. The mutational landscape of adenoid cystic carcinoma. Nat Genet. 2013; 45(7):791-798.
33. Quintana AM, Liu F, O'Rourke JP and Ness SA. Identification and regulation of c-Myb target genes in MCF-7 cells. BMC cancer. 2011; 11:30.
34. Holst VA, Marshall CE, Moskaluk CA and Frierson HF, Jr. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 1999; 12(10):956-960.
35. Ding L, Zhu SR, Xie SX and Wu XB. [Effects of basic fibroblast growth factor on the proliferation of human salivary adenoid cystic carcinoma cell line ACC-2 and extracellular signal-regulated kinase, Cyclin D1, p2waf/cip1 signaling pathway]. Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology. 2008; 26(2):118-120.
36. O'Neil J and Look AT. Mechanisms of transcription factor deregulation in lymphoid cell transformation. Oncogene. 2007; 26(47):6838-6849.
37. Britos-Bray M and Friedman AD. Core binding factor cannot synergistically activate the myeloperoxidase proximal enhancer in immature myeloid cells without c-Myb. Molecular and cellular biology. 1997; 17(9):5127-5135.
38. Mertz JA, Kobayashi R and Dudley JP. ALY is a common coactivator of RUNX1 and c-Myb on the type B leukemogenic virus enhancer. Journal of virology. 2007; 81(7):3503-3513.
39. Hernandez-Munain C and Krangel MS. c-Myb and core-binding factor/PEBP2 display functional synergy but bind independently to adjacent sites in the T-cell receptor delta enhancer. Molecular and cellular biology. 1995; 15(6):3090-3099.
40. Martensson A, Xie XQ, Persson C, Holm M, Grundstrom T and Martensson IL. PEBP2 and c-myb sites crucial for lambda5 core enhancer activity in pre-B cells. European journal of immunology. 2001; 31(11):3165-3174.
41. Liu J, Park ES, Curry TE, Jr. and Jo M. Periovulatory expression of hyaluronan and proteoglycan link protein 1 (Hapln1) in the rat ovary: hormonal regulation and potential function. Molecular endocrinology (Baltimore, Md. 24(6):1203-1217.
42. Jo M and Curry TE, Jr. Luteinizing hormone-induced RUNX1 regulates the expression of genes in granulosa cells of rat periovulatory follicles. Molecular endocrinology (Baltimore, Md. 2006; 20(9):2156-2172.
43. Liu X, Ory V, Chapman S, Yuan H, Albanese C, Kallakury B, Timofeeva OA, Nealon C, Dakic A, Simic V, Haddad BR, Rhim JS, Dritschilo A, Riegel A, McBride A and Schlegel R. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. The American journal of pathology. 2012; 180(2):599-607.
44. Ricciardelli C, Sakko AJ, Ween MP, Russell DL and Horsfall DJ. The biological role and regulation of versican levels in cancer. Cancer metastasis reviews. 2009; 28(1-2):233-245.
45. Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A and Levitt M. A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral oncology. 2007; 43(1):33-36.
46. Agulnik M, Cohen EW, Cohen RB, Chen EX, Vokes EE, Hotte SJ, Winquist E, Laurie S, Hayes DN, Dancey JE, Brown S, Pond GR, Lorimer I, Daneshmand M, Ho J, Tsao MS, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol. 2007; 25(25):3978-3984.
47. Mitani Y, Li J, Rao PH, Zhao YJ, Bell D, Lippman SM, Weber RS, Caulin C and El-Naggar AK. Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010; 16(19):4722-4731.
48. Mitani Y, Rao PH, Futreal PA, Roberts DB, Stephens PJ, Zhao YJ, Zhang L, Mitani M, Weber RS, Lippman SM, Caulin C and El-Naggar AK. Novel chromosomal rearrangements and break points at the t(6;9) in salivary adenoid cystic carcinoma: association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcome. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17(22):7003-7014.
49. Brill LB, 2nd, Kanner WA, Fehr A, Andren Y, Moskaluk CA, Loning T, Stenman G and Frierson HF, Jr. Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2011; 24(9):1169-1176.
50. Costa AF, Altemani A, Garcia-Inclan C, Fresno F, Suarez C, Llorente JL and Hermsen M. Analysis of MYB oncogene in transformed adenoid cystic carcinomas reveals distinct pathways of tumor progression. Laboratory investigation; a journal of technical methods and pathology. 2014; 94(6):692-702.
51. Friedman AD. Runx1, c-Myb, and C/EBPalpha couple differentiation to proliferation or growth arrest during hematopoiesis. Journal of cellular biochemistry. 2002; 86(4):624-629.
52. Carabana J, Ortigoza E and Krangel MS. Regulation of the murine Ddelta2 promoter by upstream stimulatory factor 1, Runx1, and c-Myb. Journal of immunology. 2005; 174(7):4144-4152.
53. Mansour MR, Abraham BJ, Anders L, Berezovskaya A, Gutierrez A, Durbin AD, Etchin J, Lawton L, Sallan SE, Silverman LB, Loh ML, Hunger SP, Sanda T, Young RA, Look AT. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science. 2014.
54. Burns CE, Galloway JL, Smith AC, Keefe MD, Cashman TJ, Paik EJ, Mayhall EA, Amsterdam AH and Zon LI. A genetic screen in zebrafish defines a hierarchical network of pathways required for hematopoietic stem cell emergence. Blood. 2009; 113(23):5776-5782.
55. Rothenberg EV. Regulatory factors for initial T lymphocyte lineage specification. Current opinion in hematology. 2007; 14(4):322-329.
56. Zaiman AL and Lenz J. Transcriptional activation of a retrovirus enhancer by CBF (AML1) requires a second factor: evidence for cooperativity with c-Myb. Journal of virology. 1996; 70(8):5618-5629.
57. Pattabiraman DR, McGirr C, Shakhbazov K, Barbier V, Krishnan K, Mukhopadhyay P, Hawthorne P, Trezise A, Ding J, Grimmond SM, Papathanasiou P, Alexander WS, Perkins AC, Levesque JP, Winkler IG and Gonda TJ. Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes. Blood. 2014; 123(17):2682-2690.
58. Bresciani E, Carrington B, Wincovitch S, Jones M, Gore AV, Weinstein BM, Sood R, Liu PP. CBFβ and RUNX1 are required at 2 different steps during the development of hematopoietic stem cells in zebrafish. Blood. 2014; 124(1):9.
59. Del Real MM and Rothenberg EV. Architecture of a lymphomyeloid developmental switch controlled by PU.1, Notch and Gata3. Development. 2013; 140(6):1207-1219.
60. Dupuis LE, Osinska H, Weinstein MB, Hinton RB and Kern CB. Insufficient versican cleavage and Smad2 phosphorylation results in bicuspid aortic and pulmonary valves. Journal of molecular and cellular cardiology. 2013; 60:50-59.
61. Goldoni S and Iozzo RV. Tumor microenvironment: Modulation by decorin and related molecules harboring leucine-rich tandem motifs. International journal of cancer Journal international du cancer. 2008; 123(11):2473-2479.
62. Schaefer L and Schaefer RM. Proteoglycans: from structural compounds to signaling molecules. Cell and tissue research. 2010; 339(1):237-246.
63. Ivanova AV, Goparaju CM, Ivanov SV, Nonaka D, Cruz C, Beck A, Lonardo F, Wali A and Pass HI. Protumorigenic role of HAPLN1 and its IgV domain in malignant pleural mesothelioma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15(8):2602-2611.
64. Touab M, Villena J, Barranco C, Arumi-Uria M and Bassols A. Versican is differentially expressed in human melanoma and may play a role in tumor development. The American journal of pathology. 2002; 160(2):549-557.
65. Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, Zaid TM, Ghosh S, Birrer MJ and Mok SC. TGF-beta modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res. 2013; 73(16):5016-5028.
66. Kischel P, Waltregny D, Dumont B, Turtoi A, Greffe Y, Kirsch S, De Pauw E and Castronovo V. Versican overexpression in human breast cancer lesions: known and new isoforms for stromal tumor targeting. International journal of cancer Journal international du cancer. 2010; 126(3):640-650.
67. Gorter A, Zijlmans HJ, van Gent H, Trimbos JB, Fleuren GJ and Jordanova ES. Versican expression is associated with tumor-infiltrating CD8-positive T cells and infiltration depth in cervical cancer. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2010; 23(12):1605-1615.
68. Miquel-Serra L, Serra M, Hernandez D, Domenzain C, Docampo MJ, Rabanal RM, de Torres I, Wight TN, Fabra A and Bassols A. V3 versican isoform expression has a dual role in human melanoma tumor growth and metastasis. Laboratory investigation; a journal of technical methods and pathology. 2006; 86(9):889-901.
69. Frierson HF, Jr., El-Naggar AK, Welsh JB, Sapinoso LM, Su AI, Cheng J, Saku T, Moskaluk CA and Hampton GM. Large scale molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinoma. The American journal of pathology. 2002; 161(4):1315-1323.
70. Pratheepa L PR, Herald J Sherlin, Anuja N, Priya Premkumar. Expression of Emerging Novel Tumor markers in Oral Squamous cell carcinoma and their Clinical and Pathological correlation to determine the Prognosis and Usefulness as a Therapeutic target - A Systematic Review. Journal of Natural Sciences Research. 2012; 2(1).
71. Pirinen R, Leinonen T, Bohm J, Johansson R, Ropponen K, Kumpulainen E and Kosma VM. Versican in nonsmall cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis. Human pathology. 2005; 36(1):44-50.
72. Barczak A, Rodriguez MW, Hanspers K, Koth LL, Tai YC, Bolstad BM, Speed TP and Erle DJ. Spotted long oligonucleotide arrays for human gene expression analysis. Genome research. 2003; 13(7):1775-1785.
73. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B and Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic acids research. 2003; 31(4):e15.
74. Hochberg Y and Benjamini Y. More powerful procedures for multiple significance testing. Statistics in medicine. 1990; 9(7):811-818.
75. Chen Z, Chen J, Gu Y, Hu C, Li JL, Lin S, Shen H, Cao C, Gao R, Li J, Ha PK, Kaye FJ, Griffin JD and Wu L. Aberrantly activated AREG-EGFR signaling is required for the growth and survival of CRTC1-MAML2 fusion-positive mucoepidermoid carcinoma cells. Oncogene. 2013.
76. Azuma M, Tamatani T, Kasai Y and Sato M. Immortalization of normal human salivary gland cells with duct-, myoepithelial-, acinar-, or squamous phenotype by transfection with SV40 ori- mutant deoxyribonucleic acid. Laboratory investigation; a journal of technical methods and pathology. 1993; 69(1):24-42.
77. Yan Y, Salazar TE, Dominguez JM, 2nd, Nguyen DV, Li Calzi S, Bhatwadekar AD, Qi X, Busik JV, Boulton ME and Grant MB. Dicer expression exhibits a tissue-specific diurnal pattern that is lost during aging and in diabetes. PloS one. 2013; 8(11):e80029.
78. Schneider CA, Rasband WS and Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nature methods. 2012; 9(7):671-675.
79. Zajac-Kaye M and Ts'o PO. DNAase I encapsulated in liposomes can induce neoplastic transformation of Syrian hamster embryo cells in culture. Cell. 1984; 39(3 Pt 2):427-437.